OUR GOALS

RHU SPRINT – Synergy to accelerate therapeutic innovation in cutaneous T lymphoma

 

The SPRINT project aims to transform the care of patients with cutaneous T-cell lymphomas. These diseases affect 1 in 100,000 people every year, and their incidence has risen sharply in recent decades. This pathology severely impairs patients’ quality of life through skin damage, secondary skin infections, pain and fatigue, and survival is reduced in the advanced stages of the disease. Even today, only a minority of patients respond satisfactorily to existing treatments, and the disease is generally considered incurable.

Project leader: Professor Adèle de Masson, PU-PH – Université Paris Cité / AP-HP

Scientific and technic Leader: Professor Hélène Moins, PU-PH – Université Paris Cité / inserm

Coordinating University: Université Paris Cité

Partners: AP-HP Hospitals, Domain Therapeutics, CHU Bordeaux (University Hospital of Bordeaux), Hospices Civils de Lyon (Civil Hospitals of Lyon), Inserm, TheraPanacea, ELLyE (Leukemia Lymphoma patient association), European Reference Network for Rare Hematological Diseases, GFELC (French Study Group of Cutaneous Lymphomas).

Budget: This project is supported by the State with 9 664 690 euros, which is managed by the National Research Agency (ANR) under the France 2030 programme, the project reference being ANR-23-RHUS-0009.